Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.95 USD | -0.38% | -6.58% | -22.89% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
End-of-day quotes
Sector Other Advanced Medical Equipment & Technology
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
230M | - | |||||
227B | ||||||
198B | ||||||
142B | ||||||
111B | ||||||
64.16B |
- Stock Market
- Equities
- NPCE Stock
- Charts NeuroPace, Inc.
- Sector Chart